Food industry by-products represent an abundant and underexploited source of bioactive compounds, dietary fibers and proteins with significant potential for functional food development. Recent studies estimate that up to 30 to 50% of processed raw materials are discarded as by-products, while food waste contributes approximately 8–10% of global greenhouse gas emissions, equivalent to nearly 3.3 billion tons of CO₂ annually. This review critically evaluates advances (2015–2026) in the valorization of food industry by-products, with a focus on technological efficiency, health-related evidence, and environmental impact. Specifically, it addresses the following research question: to what extent do current valorization strategies provide measurable technological, nutritional, and environmental advantages over conventional food production systems? Emerging extraction technologies including ultrasound- and microwave-assisted extraction (20–40 kHz, 30–60 °C), supercritical fluid extraction (200–350 bar, 35–60 °C), enzymatic hydrolysis, and fermentation demonstrated improvements in extraction yields (up to 20–50% increases compared to conventional methods) and higher purity in the recovered compounds. These approaches enable the isolation of compounds such as pectins from citrus peels, polyphenols from grape pomace, galacto-oligosaccharides from dairy whey, and collagen from fish by-products. From an environmental perspective, valorization strategies can reduce waste disposal and associated emissions by up to 30%, depending on the scale and type of by-product processing. Furthermore, these approaches contribute directly to circular economy models and support multiple Sustainable Development Goals, particularly SDG 12 (responsible consumption and production) and SDG 13 (climate action). However, challenges remain, including variability in raw material composition, scalability limitations, and the limited availability of high-quality clinical evidence supporting health benefits. By integrating nutritional potential, technological feasibility, and sustainability indicators, this review provides a comprehensive and critical assessment of the current state of by-product valorization and identifies key gaps for future research.

Canine mammary carcinomas (CMC) are associated with major aggressive clinical behavior and high mortality. The current standard of care is based on surgical resection, without an established effective treatment scheme, highlighting the urgent need to develop novel effective therapies. Vascular endothelial growth factor (VEGF) is a key regulator of tumor angiogenesis and progression in the majority of solid cancers, including human and canine mammary carcinomas. The first therapy developed to target VEGF was bevacizumab, a recombinant humanized monoclonal antibody, which has already been approved as an anticancer agent in several human cancers. The goal of this work was to establish the therapeutic value of MB02 bevacizumab biosimilar in CMC. First, through different in silico approaches using the MUSCLE multiple-sequence alignment tool and the FoldX protein design algorithm, we were able to predict that canine VEGF is recognized by bevacizumab, after showing an extremely high sequence similarity between canine and human VEGF. Further, by using an ELISA-based in vitro binding assay, we confirmed that MB02 biosimilar was able to recognize canine VEGF. Additionally, canine VEGF-induced microvascular endothelial cell proliferation was inhibited in a concentration-dependent manner by MB02 biosimilar. These encouraging results show a high potential for MB02 as a promising therapeutic agent for the management of CMC.

Several reviews of denitrification have shown it to be an efficient process for treating high nitrate-loaded effluents from nuclear industries. However, stressful conditions adversely affect biological kinetic parameters and performance. Additionally, actual nuclear effluents contain multiple pollutants and radioactive emissions that could render implementation difficult. The objective of this study was to treat and recycle water from nuclear industries by using a mixture of blended real nuclear wastewater (BRNW). The process was carried out under physicochemical parameters control in a biological model to established a technical setup and to model the denitrification process in a real nuclear wastewater effluent. Denitrification processes were carried out in the wastewater sample under controlled ORP conditions by the Hill model to establish the kinetic model. The results show a complete elimination of nitrate by the bacteria. Indicators of biochemical reactions were used to obtain a model based on Monod and controlled ORP. The good fit of the proposed model was verified under empirical and simulated conditions. To establish optimal performance, it was necessary to add 3% v/v of methanol, as a carbon source, to remove the nitrate in BRNW. Isolation techniques confirmed that Pseudomonas spp. was the dominant bacteria. Gene expression demonstrated the lack of inhibition of the NosZ gene responsible for the reduction in nitric oxide, a “greenhouse gas”. Finally, COD and uranium were removed from the liquid by precipitation. At the end of the process, the treated effluent could potentially be reused in industrial processes, recycling most of the wastewater effluents.